Enhancing bispecific antibody therapies with healthy donor T cells

• Unité de recherche: INNOSUISSE
• Numéro de projet: 100.763 IP-LS
• Titre du projet anglais: Enhancing bispecific antibody therapies with healthy donor T cells

Mots-clé (Anglais)

Life sciences, Human medicine

Résumé des résultats (Abstract) (Anglais)

Bispecific antibodies (biAbs) rely on autologous T cells which, in cancer patients, are often insufficient. Encelta has developed Allogeneic-Engineered-Decoupled (AED) T cells from healthy donors that can be used safely (no GvHD) and effectively against tumor cells when activated with a biAb.